Zoetis Inc. (ZTS)
ZTS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$74.30
-1.78% on the day
Market cap
$30.7B
Large cap
Revenue · 2025
$9.5B
+2.3% on 2024
Net income · 2025
$2.7B
28.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ZTS on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2013 |
| SEC CIK | 0001555280 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $9.5B |
| Net income | $2.7B |
| Operating income | Not in SEC XBRL data |
| Net margin | 28.2% |
| Operating margin | Operating income not reported |
| Revenue growth | +2.3% |
| Cash | $2.5B |
| Total assets | $15.5B |
| P/E (computed) | 11.5× |
| P/S (computed) | 3.2× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-08-12 |
| Latest annual report | 10-K | 2026-02-12 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-13 |
| Latest proxy | DEFA14A | 2026-04-08 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.9% |
| 1 month | +3.2% |
| 3 months | -1.4% |
| Year to date | -39.8% |
| 1 year | -46.7% |
| From 52-week high | -48.6% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals Inc. | $223.82 | -1.41% | $29.9B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $56.57 | -2.09% | $32.5B |
| ROIV | Roivant Sciences Ltd. Common Shares | $33.35 | -3.58% | $24.1B |
| ONC | BeOne Medicines Ltd. | $349.08 | -0.38% | $39.7B |
| UTHR | United Therapeutics Corporation | $543.40 | -1.22% | $23.3B |
| GMAB | Genmab A/S ADS | $36.57 | -2.14% | $22.8B |
| INSM | Insmed Incorporated | $96.79 | -1.80% | $21.1B |
| VTRS | Viatris Inc. | $17.25 | -1.65% | $19.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier